Kazuko Kudo

Kazuko Kudo

Auto-generated profile, based on publicly available information

Kazuko Kudo

Department of Pediatrics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2009 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
KKK Kudo
K Kudo
SOS Ohga
S Ohga
AMA Morimoto
A Morimoto
YIY Ishida
Y Ishida
NSN Suzuki
N Suzuki
EIE Ishii
E Ishii

1 September 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
DTDaisuke Tomizawa
Daisuke Tomizawa
STShiro Tanaka
Shiro Tanaka
TKTadakazu Kondo
Tadakazu Kondo
YHYoshiko Hashii
Yoshiko Hashii
YAYasuyuki Arai
Yasuyuki Arai
HIHiroyuki Ishida
Hiroyuki Ishida
Few reports have focused on adolescent and young adult (AYA) patients with acute myeloid leukemia (AML) treated with hematopoietic stem cell transplantation (HSCT). We performed a retrospective analysis based on data obtained from a Japanese nationwide registration database to compare HSCT outcomes in AYA patients with AML with those in children with AML. An analysis of the 2973 patients with de novo AML who received allogeneic HSCT from 1990 to 2013 showed inferior 5-year overall survival (OS) (54% versus 58%, P <.01) and increased treatment-related mortality (TRM) (16% versus 13%, P = .02) in AYA patients. Multivariate analysis for both OS and TRM showed a significant negative impact on AYAs. However, the negative impact of older age lost its significance in an additional analysis focusing on 1407 recent transplant recipients with high-resolution HLA typing (2000 to 2013). Finally, we analyzed the impact of transplantation center type on HSCT outcomes in 317 adolescent patients (15 to 18 years old) and found no difference in outcomes between patients treated at a pediatric or an adult hospital. Higher age was a strong predictive factor for inferior OS resulting from increased TRM, which can be eliminated with better donor selection using high-resolution HLA typing.

4 February 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
YOYasuhiro Okamoto
Yasuhiro Okamoto
KKKazuko Kudo
Kazuko Kudo
KTKen Tabuchi
Ken Tabuchi
DTDaisuke Tomizawa
Daisuke Tomizawa
TTTakashi Taga
Takashi Taga
HIHiroyuki Ishida
Hiroyuki Ishida
Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58%). The 3-year overall survival (OS) rate was 23% (95% confidence interval [CI]: 19-28%). Chronic GVHD was associated with improved 3-year OS (47%, 95% CI, 36-57%, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25% of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1-2, 3-4, 5, and 6-7 pre-HSCT variables had 3-year OS rates of 52%, 32%, 19%, 8, and 0%, respectively. Our findings may help experts decide if HSCT should be performed in such cases.

28 October 2016 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
YKYoshiki Kawamura
Yoshiki Kawamura
HMHiroki Miura
Hiroki Miura
YMYuji Matsumoto
Yuji Matsumoto
HUHidetoshi Uchida
Hidetoshi Uchida
KKKazuko Kudo
Kazuko Kudo
TYTetsushi Yoshikawa
Tetsushi Yoshikawa
Hemophagocytic lymphohistiocytosis (HLH) is a life threatening hematological disorder associated with severe systemic inflammation caused by an uncontrolled and ineffective immune response resulting in cytokine storm. Epstein-Barr virus (EBV) is the most common infectious agent in patients with the viral-associated HLH. Limited numbers of cases with cardiac complication have been demonstrated in other viral-associated HLH patients. Herein, we report a pediatric case of severe EBV-associated HLH with cardiac complications. A previously healthy 4-year-old Japanese female was admitted to a local hospital with a four day history of fever. Despite antibiotic treatment, her fever persisted to day 7 of the illness. Finally, the diagnosis of HLH was confirmed by fulfilling diagnostic criteria for HLH and pathological analysis of bone marrow aspiration. Real-time PCR detected a high copy number of EBV DNA in the peripheral blood mononuclear cells (PBMCs) at the time of hospital admission. During treatment according to HLH-2004 protocol, sudden cardiopulmonary arrest (CPA) occurred on day 30 of the illness and immediate resuscitation was successful. Acute myocarditis was considered the cause of the CPA. Although the treatment regimen was completed on day 88 of the illness, a remarkably high copy number of EBV DNA was still detected in her PBMCs. Based on our flow cytometric in situ hybridization analysis that revealed EBV infection of only B lymphocytes, we decided to administer rituximab to control the abnormal EBV infection. Afterwards the amount of EBV DNA decreased gradually to undetectable level on day 130 of the illness. Unfortunately, a coronary artery aneurysm was discovered at the left main coronary artery on day 180 of the illness. Finally, the patient was discharged from the hospital on day 203 of the illness without sequelae except for a coronary aneurysm. In this case report, EBV-HLH was complicated with cardiac symptoms such as myocarditis and coronary artery aneurysm. Although remarkably high copy number of EBV DNA was detected in PBMCs after completion of the HLH-2004 protocol, rituximab treatment resulted in a dramatic decrease of EBV DNA to undetectable levels. Rituximab treatment might have been beneficial for the patient’s survival.

22 November 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
THThe Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology
The Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology
KKKazuko Kudo
Kazuko Kudo
MMMiho Maeda
Miho Maeda
NSNobuhiro Suzuki
Nobuhiro Suzuki
HKHirokazu Kanegane
Hirokazu Kanegane
AMAkira Morimoto
Akira Morimoto

12 February 2018 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
HMHiroki Miura
Hiroki Miura
FHFumihiko Hattori
Fumihiko Hattori
HUHidetoshi Uchida
Hidetoshi Uchida
THTadayoshi Hata
Tadayoshi Hata
KKKazuko Kudo
Kazuko Kudo
TYTetsushi Yoshikawa
Tetsushi Yoshikawa
Respiratory syncytial virus (RSV) infection is common and may be severe among patients with preexisting cardiac anomalies, but direct involvement of myocardial damage is not common in those patients. Additionally, myocardial involvement has been rarely described among immune compromised children. A 4-year-old girl with acute lymphoblastic leukemia who received maintenance chemotherapy in an outpatient clinic developed systemic inflammatory response syndrome. RSV infection was confirmed by a positive rapid antigen test and serological assay. Subsequently, she was diagnosed with severe myocarditis caused by RSV infection, which was diagnosed by abnormal findings of cardiac echography and ECG and elevated biomarkers for myocardial damage. Then, she was treated in the intensive care unit for 13 days. High amounts of RSV type B RNA was detected in tracheal aspirates and serum sample. This case report emphasizes that RSV infection may be associated with myocarditis in immunocompromised children receiving maintenance chemotherapy.